SIRT1: A Novel Target for the Treatment of Muscular Dystrophies

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Kuno, Atsushi ^a   Horio, Yoshiyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; PROTEINS;

BENEFICIAL EFFECTS; CELLULAR PROCESS; CYTOSKELETAL PROTEINS; DUCHENNE MUSCULAR DYSTROPHIES; MOLECULAR MECHANISM; MUSCULAR DYSTROPHY; STRESS RESISTANCE; THERAPEUTIC TARGETS;

MAMMALS;

SIRTUIN 1;

ANIMAL MODEL; ANTIOXIDANT ACTIVITY; DRUG TARGETING; HUMAN; INFLAMMATION; MUSCULAR DYSTROPHY; MYOFIBROSIS; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; REVIEW; SKELETAL MUSCLE; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; METABOLISM; MOLECULARLY TARGETED THERAPY; MUSCULAR DYSTROPHIES;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MUSCULAR DYSTROPHIES; SIRTUIN 1;

EID: 84962898792     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/6714686     Document Type: Review

References (110)

1. E. Mercuri and F. Muntoni, "Muscular dystrophies, " The Lancet, vol. 381, no. 9869, pp. 845-860, 2013.
2. T. Voit, H. Topaloglu, V. Straub et al., "Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMANDII): An exploratory, randomised, placebo-controlled phase 2 study, "TheLancetNeurology, vol. 13, no. 10, pp. 987-996, 2014.
3. P. B. Kang and R. C. Griggs, "Advances inmuscular dystrophies, " JAMA Neurology, vol. 72, no. 7, pp. 741-742, 2015.
4. R. S. Finkel, K. M. Flanigan, B. Wong et al., "Phase 2a study of ataluren-mediated dystrophin production in patients with nonsensemutation Duchennemuscular dystrophy, " PLoS ONE, vol. 8, no. 12, Article ID e81302, 2013.
5. J. Finsterer and L. Cripe, "Treatment of dystrophin cardiomyopathies, " Nature Reviews Cardiology, vol. 11, no. 3, pp. 168-179, 2014.
6. S. V. Raman, K. N. Hor, W. Mazur et al., "Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: A randomised, double-blind, placebo-controlled trial, "The Lancet Neurology, vol. 14, no. 2, pp. 153-161, 2015.
7. Y. Horio, T. Hayashi, A. Kuno, and R. Kunimoto, "Cellular and molecular effects of sirtuins in health and disease, " Clinical Science, vol. 121, no. 5, pp. 191-203, 2011.
8. J. Tonkin, F. Villarroya, P. L. Puri, and M. Vinciguerra, "SIRT1 signaling as potential modulator of skeletal muscle diseases, " Current Opinion in Pharmacology, vol. 12, no. 3, pp. 372-376, 2012.
9. M. Vinciguerra, M. Fulco, A. Ladurner, V. Sartorelli, and N. Rosenthal, "SirT1 in muscle physiology and disease: lessons from mouse models, " Disease Models & Mechanisms, vol. 3, no. 5-6, pp. 298-303, 2010.
10. Y. S. Hori, A. Kuno, R. Hosoda et al., "Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy, " Journal of Pharmacology and Experimental Therapeutics, vol. 338, no. 3, pp. 784-794, 2011.
11. K. T. Howitz, K. J. Bitterman, H. Y. Cohen et al., "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan, " Nature, vol. 425, no. 6954, pp. 191-196, 2003.
12. S.-I. Imai, C. M. Armstrong, M. Kaeberlein, and L. Guarente, "Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase, " Nature, vol. 403, no. 6771, pp. 795-800, 2000.
13. J. T. Rodgers, C. Lerin, W. Haas, S. P. Gygi, B. M. Spiegelman, and P. Puigserver, "Nutrient control of glucose homeostasis through a complex of PGC-1 and SIRT1, " Nature, vol. 434, no. 7029, pp. 113-118, 2005.
14. Z. Gerhart-Hines, J. T. Rodgers, O. Bare et al., "Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1, " EMBO Journal, vol. 26, no. 7, pp. 1913-1923, 2007.
15. J. T. Rodgers and P. Puigserver, "Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 31, pp. 12861-12866, 2007.
16. J. T. Selsby, K. J. Morine, K. Pendrak, E. R. Barton, and H. L. Sweeney, "Rescue of dystrophic skeletal muscle by PGC-1 involves a fast to slow fiber type shift in the mdx mouse, " PLoS ONE, vol. 7, no. 1, Article ID e30063, 2012.
17. B. S. Gordon, D. C. Delgado Diáz, and M. C. Kostek, "Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy, " Clinical Nutrition, vol. 32, no. 1, pp. 104-111, 2013.
18. B. S. Gordon, D. C. Delgado-Diaz, J. Carson, R. Fayad, L. B. Wilson, and M. C. Kostek, "Resveratrol improves muscle function but not oxidative capacity in young mdx mice, " Canadian Journal of Physiology and Pharmacology, vol. 92, no. 3, pp. 243-251, 2014.
19. V. Ljubicic, M. Burt, J. A. Lunde, and B. J. Jasmin, "Resveratrol induces expression of the slow, oxidative phenotype in Mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1 axis, " The American Journal of Physiology-Cell Physiology, vol. 307, no. 1, pp. C66-C82, 2014.
20. J. A. Baur, K. J. Pearson, N. L. Price et al., "Resveratrol improves health and survival of mice on a high-calorie diet, " Nature, vol. 444, no. 7117, pp. 337-342, 2006.
21. S.-J. Park, F. Ahmad, A. Philp et al., "Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases, " Cell, vol. 148, no. 3, pp. 421-433, 2012.
22. A. Chalkiadaki, M. Igarashi, A. S. Nasamu, J. Knezevic, and L. Guarente, "Muscle-specific SIRT1 gain-of-function increases slow-twitch fibers and ameliorates pathophysiology in a mouse model of duchennemuscular dystrophy, " PLoS Genetics, vol. 10, no. 7, Article IDe1004490, 2014.
23. A. Kuno, M. Tanno, and Y. Horio, "The effects of resveratrol and SIRT1 activation on dystrophic cardiomyopathy, " Annals of the New York Academy of Sciences, vol. 1348, no. 1, pp. 46-54, 2015.
24. M. Tanno, A. Kuno, T. Yano et al., "Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure, " The Journal of Biological Chemistry, vol. 285, no. 11, pp. 8375-8382, 2010.
25. A. M. Blain and V. W. Straub, "-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches, " Skeletal Muscle, vol. 1, no. 1, article13, 2011.
26. A. Kuno, Y. S. Hori, R. Hosoda et al., "Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of p300 protein, " The Journal of Biological Chemistry, vol. 288, no. 8, pp. 5963-5972, 2013.
27. J.-H. Kim, H.-B. Kwak, L. V. Thompson, and J. M. Lawler, "Contribution of oxidative stress to pathology in diaphragmand limb muscles with Duchenne muscular dystrophy, " Journal of Muscle Research and Cell Motility, vol. 34, no. 1, pp. 1-13, 2013.
28. M. C. Rodriguez and M. A. Tarnopolsky, "Patients with dystrophinopathy showevidence of increased oxidative stress, " Free Radical Biology andMedicine, vol. 34, no. 9, pp. 1217-1220, 2003.
29. R. Renjini, N. Gayathri, A. Nalini, and M. M. S. Bharath, "Oxidative damage in muscular dystrophy correlates with the severity of the pathology: role of glutathione metabolism, " Neurochemical Research, vol. 37, no. 4, pp. 885-898, 2012.
30. M.-H. Disatnik, J. Dhawan, Y. Yu et al., "Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state, " Journal of the Neurological Sciences, vol. 161, no. 1, pp. 77-84, 1998.
31. N. P. Whitehead, C. Pham, O. L. Gervasio, and D. G. Allen, "Nacetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice, " The Journal of Physiology, vol. 586, no. 7, pp. 2003-2014, 2008.
32. J. R. Terrill, H. G. Radley-Crabb, M. D. Grounds, and P. G. Arthur, "N-Acetylcysteine treatment of dystrophic mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosis, " Neuromuscular Disorders, vol. 22, no. 5, pp. 427-434, 2012.
33. J.-H. Kim and J. M. Lawler, "Amplification of proinflammatory phenotype, damage, and weakness by oxidative stress in the diaphragm muscle of mdx mice, " Free Radical Biology and Medicine, vol. 52, no. 9, pp. 1597-1606, 2012.
34. J. D. Lambeth, T. Kawahara, and B. Diebold, "Regulation of Nox and Duox enzymatic activity and expression, " Free Radical Biology and Medicine, vol. 43, no. 3, pp. 319-331, 2007.
35. N. P. Whitehead, E. W. Yeung, S. C. Froehner, and D. G. Allen, "Skeletal muscle NADPH oxidase is increased and triggers stretch-induced damage in the mdx mouse, " PLoS ONE, vol. 5, no. 12, Article ID e15354, 2010.
36. V. M. Shkryl, A. S. Martins, N. D. Ullrich, M. C. Nowycky, E. Niggli, and N. Shirokova, "Reciprocal amplification of ROS and Ca2+ signals in stressed mdx dystrophic skeletal muscle fibers, " Pflugers Archiv-European Journal of Physiology, vol. 458, no. 5, pp. 915-928, 2009.
37. N. P. Whitehead, M. J. Kim, K. L. Bible, M. E. Adams, and S. C. Froehner, "A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 41, pp. 12864-12869, 2015.
38. R. Pal, M. Palmieri, J. A. Loehr et al., "Src-dependent impairment of autophagy by oxidative stress in a mouse model of Duchennemuscular dystrophy, "Nature Communications, vol. 5, article 4425, 2014.
39. A. Sturrock, T. P. Huecksteadt, K. Norman et al., "Nox4 mediates TGF-1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smoothmuscle cells, " The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 292, no. 6, pp. L1543-L1555, 2007.
40. L. Hecker, R. Vittal, T. Jones et al., "NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury, " Nature Medicine, vol. 15, no. 9, pp. 1077-1081, 2009.
41. J. Li, X. Qu, S. D. Ricardo, J. F. Bertram, and D. J. Nikolic-Paterson, "Resveratrol inhibits renal fibrosis in the obstructed kidney: Potential role in deacetylation of Smad3, " American Journal of Pathology, vol. 177, no. 3, pp. 1065-1071, 2010.
42. X.-Z. Huang, D. Wen, M. Zhang et al., "Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-/Smad3 pathway, " Journal of Cellular Biochemistry, vol. 115, no. 5, pp. 996-1005, 2014.
43. H. Huang and D. J. Tindall, "Dynamic FoxO transcription factors, " Journal of Cell Science, vol. 120, no. 15, pp. 2479-2487, 2007.
44. H. Daitoku, M. Hatta, H. Matsuzaki et al., "Silent information regulator 2 potentiates Foxo 1-mediated transcription through its deacetylase activity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 27, pp. 10042-10047, 2004.
45. A. Brunet, L. B. Sweeney, J. F. Sturgill et al., "Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase, " Science, vol. 303, no. 5666, pp. 2011-2015, 2004.
46. A. van der Horst, L. G. J. Tertoolen, L. M. M. De Vries-Smits, R. A. Frye, R. H. Medema, and B. M. T. Burgering, "FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir21, " Journal of Biological Chemistry, vol. 279, no. 28, pp. 28873-28879, 2004.
47. Y. Kobayashi, Y. Furukawa-Hibi, C. Chen et al., "SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress, " International Journal ofMolecularMedicine, vol. 16, no. 2, pp. 237-243, 2005.
48. M. Tanno, J. Sakamoto, T. Miura, K. Shimamoto, and Y. Horio, "Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1, " The Journal of Biological Chemistry, vol. 282, no. 9, pp. 6823-6832, 2007.
49. Y. S. Hori, A. Kuno, R. Hosoda, and Y. Horio, "Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress, " PLoS ONE, vol. 8, no. 9, Article ID e73875, 2013.
50. R. Hosoda, A. Kuno, Y. S. Hori et al., "Differential cell-protective function of two resveratrol (trans-3, 5, 4-trihydroxystilbene) glucosides against oxidative stress, " Journal of Pharmacology and ExperimentalTherapeutics, vol. 344, no. 1, pp. 124-132, 2013.
51. A. J. Kriegel, Y. Fang, Y. Liu et al., "MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor 1: A novel role of miR-382, " Nucleic Acids Research, vol. 38, no. 22, pp. 8338-8347, 2010.
52. S. C. Lu, "Glutathione synthesis, " Biochimica et Biophysica Acta (BBA)-General Subjects, vol. 1830, no. 5, pp. 3143-3153, 2013.
53. H. Zhang, K. J. Davies, and H. J. Forman, "Oxidative stress response and Nrf2 signaling in aging, " Free Radical Biology and Medicine, vol. 88, pp. 314-336, 2015.
54. A. E. H. Emery, "The muscular dystrophies, " The Lancet, vol. 359, no. 9307, pp. 687-695, 2002.
55. C. Dogra, D. S. Srivastava, and A. Kumar, "Protein-DNA arraybased identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophindeficient mdx mice, " Molecular and Cellular Biochemistry, vol. 312, no. 1-2, pp. 17-24, 2008.
56. F. Yeung, J. E. Hoberg, C. S. Ramsey et al., "Modulation of NF-B-dependent transcription and cell survival by the SIRT1 deacetylase, " The EMBO Journal, vol. 23, no. 12, pp. 2369-2380, 2004.
57. Y. Nie, D. M. Erion, Z. Yuan et al., "STAT3 inhibition of gluconeogenesis is downregulated by SirT1, " Nature Cell Biology, vol. 11, no. 4, pp. 492-500, 2009.
58. R. Zhang, H.-Z. Chen, J.-J. Liu et al., "SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages, "The Journal of Biological Chemistry, vol. 285, no. 10, pp. 7097-7110, 2010.
59. J. Zhang, S.-M. Lee, S. Shannon et al., "The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice, " Journal of Clinical Investigation, vol. 119, no. 10, pp. 3048-3058, 2009.
60. C. Webster, L. Silberstein, A. P. Hays, and H. M. Blau, "Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy, " Cell, vol. 52, no. 4, pp. 503-513, 1988.
61. K. Baar, A. R. Wende, T. E. Jones et al., "Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1, " The FASEB Journal, vol. 16, no. 14, pp. 1879-1886, 2002.
62. H. Pilegaard, B. Saltin, and D. P. Neufer, "Exercise induces transient transcriptional activation of the PGC-1 gene in human skeletalmuscle, " Journal of Physiology, vol. 546, no. 3, pp. 851-858, 2003.
63. J. Lin, H. Wu, P. T. Tarr et al., "Transcriptional co-activator PGC-1 drives the formation of slow-twitch muscle fibres, " Nature, vol. 418, no. 6899, pp. 797-801, 2002.
64. T. J. Kelly, C. Lerin, W. Haas, S. P. Gygi, and P. Puigserver, "GCN5-mediated transcriptional control of themetabolic coactivator PGC-1 through lysine acetylation, " Journal of Biological Chemistry, vol. 284, no. 30, pp. 19945-19952, 2009.
65. M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., "Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1, " Cell, vol. 127, no. 6, pp. 1109-1122, 2006.
66. R. C. Scarpulla, R. B. Vega, and D. P. Kelly, "Transcriptional integration of mitochondrial biogenesis, " Trends in Endocrinology and Metabolism, vol. 23, no. 9, pp. 459-466, 2012.
67. I. Desguerre, M. Mayer, F. Leturcq, J.-P. Barbet, R. K. Gherardi, and C. Christov, "Endomysial fibrosis in duchenne muscular dystrophy: A marker of poor outcome associated with macrophage alternative activation, " Journal of Neuropathology and Experimental Neurology, vol. 68, no. 7, pp. 762-773, 2009.
68. R. J. Akhurst and A. Hata, "Targeting the TGF signalling pathway in disease, " Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 790-811, 2012.
69. P. Bernasconi, E. Torchiana, P. Confalonieri et al., "Expression of transforming growth factor-1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine, "The Journal of Clinical Investigation, vol. 96, no. 2, pp. 1137-1144, 1995.
70. Y.-W. Chen, K. Nagaraju, M. Bakay et al., "Early onset of inflammation and later involvement of TGF in Duchenne muscular dystrophy, " Neurology, vol. 65, no. 6, pp. 826-834, 2005.
71. J. V. Hartel, J. A. Granchelli, M. S. Hudecki, C. M. Pollina, and L. E. Gosselin, "Impact of prednisone on TGF-1 and collagen in diaphragm muscle from mdx mice, " Muscle and Nerve, vol. 24, no. 3, pp. 428-429, 2001.
72. C. A. Nelson, R. B. Hunter, L. A. Quigley et al., "Inhibiting TGF-activity improves respiratory function inmdx mice, "The American Journal of Pathology, vol. 178, no. 6, pp. 2611-2621, 2011.
73. I. Cucoranu, R. Clempus, A. Dikalova et al., "NAD(P)Hoxidase 4 mediates transforming growth factor-1-induced differentiation of cardiac fibroblasts into myofibroblasts, " Circulation Research, vol. 97, no. 9, pp. 900-907, 2005.
74. J. L. Barnes and Y. Gorin, "Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases, " Kidney International, vol. 79, no. 9, pp. 944-956, 2011.
75. A. K. Ghosh and J. Varga, "The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis, " Journal of Cellular Physiology, vol. 213, no. 3, pp. 663-671, 2007.
76. A. W. Tu and K. Luo, "Acetylation of Smad2 by the co-activator p300 regulates activin and transforming growth factor response, "The Journal of Biological Chemistry, vol. 282, no. 29, pp. 21187-21196, 2007.
77. Y. Inoue, Y. Itoh, K. Abe et al., "Smad3 is acetylated by p300/CBP to regulate its transactivation activity, " Oncogene, vol. 26, no. 4, pp. 500-508, 2007.
78. P. Simic, E. O. Williams, E. L. Bell, J. Gong, M. Bonkowski, and L. Guarente, "SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis, " Cell Reports, vol. 3, no. 4, pp. 1175-1186, 2013.
79. R. Mishra, B. L. Cool, K. R. Laderoute, M. Foretz, B. Viollet, and M. S. Simonson, "AMP-activated protein kinase inhibits transforming growth factor-induced Smad3-dependent transcription andmyofibroblast transdifferentiation, " Journal of Biological Chemistry, vol. 283, no. 16, pp. 10461-10469, 2008.
80. J.-Y. Lim, M.-A. Oh, W. H. Kim, H.-Y. Sohn, and S. I. Park, "AMP-activated protein kinase inhibits TGF-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300, " Journal of Cellular Physiology, vol. 227, no. 3, pp. 1081-1089, 2012.
81. F. Lan, J. M. Cacicedo, N. Ruderman, and Y. Ido, "SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1: Possible role in AMP-activated protein kinase activation, " Journal of Biological Chemistry, vol. 283, no. 41, pp. 27628-27635, 2008.
82. S. Jäer, C. Handschin, J. St-Pierre, and B. M. Spiegelman, "AMPactivated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12017-12022, 2007.
83. D. Vavvas, A. Apazidis, A. K. Saha et al., "Contraction-induced changes in acetyl-CoA carboxylase and 5-AMP-activated kinase in skeletal muscle, " Journal of Biological Chemistry, vol. 272, no. 20, pp. 13255-13261, 1997.
84. G. F. Merrill, E. J. Kurth, D. G. Hardie, and W. W. Winder, "AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in ratmuscle, " The American Journal of Physiology-Endocrinology and Metabolism, vol. 273, no. 6, part 1, pp. E1107-E1112, 1997.
85. E. J. Kurth-Kraczek, M. F. Hirshman, L. J. Goodyear, and W. W. Winder, "5 AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle, " Diabetes, vol. 48, no. 8, pp. 1667-1671, 1999.
86. N. L. Price, A. P. Gomes, A. J. Y. Ling et al., "SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function, " CellMetabolism, vol. 15, no. 5, pp. 675-690, 2012.
87. C. Cantó, Z. Gerhart-Hines, J. N. Feige et al., "AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity, " Nature, vol. 458, no. 7241, pp. 1056-1060, 2009.
88. M. Fulco, Y. Cen, P. Zhao et al., "Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation ofNampt, " Developmental Cell, vol. 14, no. 5, pp. 661-673, 2008.
89. C. Cantó, L. Q. Jiang, A. S. Deshmukh et al., "Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle, " Cell Metabolism, vol. 11, no. 3, pp. 213-219, 2010.
90. V. Ljubicic, P. Miura, M. Burt et al., "Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle, " Human Molecular Genetics, vol. 20, no. 17, Article ID ddr265, pp. 3478-3493, 2011.
91. V. Ljubicic, S. Khogali, J.-M. Renaud, and B. J. Jasmin, "Chronic AMPK stimulation attenuates adaptive signaling in dystrophic skeletal muscle, " The American Journal of Physiology-Cell Physiology, vol. 302, no. 1, pp. C110-C121, 2012.
92. E. Masiero, L. Agatea, C. Mammucari et al., "Autophagy is required to maintain muscle mass, " CellMetabolism, vol. 10, no. 6, pp. 507-515, 2009.
93. C. He, M. C. Bassik, V. Moresi et al., "Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis, " Nature, vol. 481, no. 7382, pp. 511-515, 2012.
94. N. Raben, V. Hill, L. Shea et al., "Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease, " Human Molecular Genetics, vol. 17, no. 24, pp. 3897-3908, 2008.
95. P. Grumati, L. Coletto, P. Sabatelli et al., "Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration, " Nature Medicine, vol. 16, no. 11, pp. 1313-1320, 2010.
96. C. De Palma, F. Morisi, S. Cheli et al., "Autophagy as a new therapeutic target inDuchennemuscular dystrophy, " Cell Death and Disease, vol. 3, article e418, 2012.
97. P. Spitali, P. Grumati, M. Hiller et al., "Autophagy is impaired in the tibialis anterior of dystrophin null mice, " PLoS Currents, vol. 5, 2013.
98. K. P. Bibee, Y.-J. Cheng, J. K. Ching et al., "Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function, " The FASEB Journal, vol. 28, no. 5, pp. 2047-2061, 2014.
99. I. H. Lee, L. Cao, R. Mostoslavsky et al., "A role for the NADdependent deacetylase Sirt1 in the regulation of autophagy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 9, pp. 3374-3379, 2008.
100. R. Huang, Y. Xu, W. Wan et al., "Deacetylation of nuclear LC3 drives autophagy initiation under starvation, " Molecular Cell, vol. 57, no. 3, pp. 456-466, 2015.
101. C. Mammucari, G. Milan, V. Romanello et al., "FoxO3 controls autophagy in skeletal muscle in vivo, " Cell Metabolism, vol. 6, no. 6, pp. 458-471, 2007.
102. J. Zhao, J. J. Brault, A. Schildet al., "FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells, " Cell Metabolism, vol. 6, no. 6, pp. 472-483, 2007.
103. N. Hariharan, Y. Maejima, J. Nakae, J. Paik, R. A. Depinho, and J. Sadoshima, "Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes, " Circulation Research, vol. 107, no. 12, pp. 1470-1482, 2010.
104. A. E. Deconinck, J. A. Rafael, J. A. Skinner et al., "Utrophindystrophin-deficient mice as a model for Duchenne muscular dystrophy, " Cell, vol. 90, no. 4, pp. 717-727, 1997.
105. B. P. Hubbard and D. A. Sinclair, "Smallmolecule SIRT1 activators for the treatment of aging and age-related diseases, " Trends in Pharmacological Sciences, vol. 35, no. 3, pp. 146-154, 2014.
106. E. Hoffmann, J. Wald, S. Lavu et al., "Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man, " British Journal of Clinical Pharmacology, vol. 75, no. 1, pp. 186-196, 2013.
107. V. Libri, A. P. Brown, G. Gambarota et al., "Apilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers, " PLoS ONE, vol. 7, no. 12, Article ID e51395, 2012.
108. S. Venkatasubramanian, R. M. Noh, S. Daga et al., "Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers, " The Journal of the American Heart Association, vol. 2, no. 3, Article ID e000042, 2013.
109. A. J. van der Meer, B. P. Scicluna, P. D. Moerland et al., "The selective sirtuin 1 activator SRT2104 reduces endotoxin-induced cytokine release and coagulation activation in humans, " Critical Care Medicine, vol. 43, no. 6, pp. e199-e202, 2015.
110. J. G. Krueger, M. Suárez-Fariñas, I. Cueto et al., "A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis, " PLOS ONE, vol. 10, no. 11, Article ID e0142081, 2015.